Is CV or ENOV more profitable?

Enovis has a net margin of -49.92% compared to CapsoVision's net margin of -198.87%. Enovis' return on equity of 10.32% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% Enovis -49.92% 10.32% 4.57%

Does the media refer more to CV or ENOV?

In the previous week, CapsoVision and CapsoVision both had 2 articles in the media. CapsoVision's average media sentiment score of 0.93 beat Enovis' score of 0.00 indicating that CapsoVision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KMTS or CV?

In the previous week, Kestra Medical Technologies had 2 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for Kestra Medical Technologies and 2 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.93 beat Kestra Medical Technologies' score of 0.47 indicating that CapsoVision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CV or PRCT?

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 2 mentions for CapsoVision. PROCEPT BioRobotics' average media sentiment score of 1.70 beat CapsoVision's score of 0.93 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CV or INSP?

In the previous week, Inspire Medical Systems had 1 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for Inspire Medical Systems and 2 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.93 beat Inspire Medical Systems' score of -0.67 indicating that CapsoVision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inspire Medical Systems 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

CapsoVision (CV) Competitors

$7.41 +0.42 (+5.99%)

Closing price 03:59 PM Eastern

Extended Trading

$7.40 -0.01 (-0.12%)

As of 04:10 PM Eastern

Compare

CV vs. ENOV, BLFS, KMTS, PRCT, and INSP

Should you buy CapsoVision stock or one of its competitors? MarketBeat compares CapsoVision with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CapsoVision include Enovis (ENOV), BioLife Solutions (BLFS), Kestra Medical Technologies (KMTS), PROCEPT BioRobotics (PRCT), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry.

How does CapsoVision compare to Enovis?

CapsoVision (NASDAQ:CV) and Enovis (NYSE:ENOV) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

CapsoVision presently has a consensus target price of $8.50, suggesting a potential upside of 14.73%. Enovis has a consensus target price of $44.50, suggesting a potential upside of 97.40%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

CapsoVision has higher earnings, but lower revenue than Enovis. CapsoVision is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	27.29	-$25.32M	-$2.34	N/A
Enovis	$2.25B	0.58	-$1.18B	-$19.88	N/A

In the previous week, CapsoVision and CapsoVision both had 2 articles in the media. CapsoVision's average media sentiment score of 0.93 beat Enovis' score of 0.00 indicating that CapsoVision is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.5% of Enovis shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Enovis has a net margin of -49.92% compared to CapsoVision's net margin of -198.87%. Enovis' return on equity of 10.32% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Enovis	-49.92%	10.32%	4.57%

Summary

Enovis beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does CapsoVision compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

93.2% of BioLife Solutions shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 2.3% of CapsoVision shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioLife Solutions has a net margin of -2.80% compared to CapsoVision's net margin of -198.87%. BioLife Solutions' return on equity of 1.81% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
CapsoVision	-198.87%	N/A	-136.03%

In the previous week, CapsoVision had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for CapsoVision and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.90 beat CapsoVision's score of 0.93 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
BioLife Solutions	Very Positive
CapsoVision	Positive

BioLife Solutions has higher revenue and earnings than CapsoVision. BioLife Solutions is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	14.55	-$4.59M	-$0.08	N/A
CapsoVision	$13.56M	27.29	-$25.32M	-$2.34	N/A

BioLife Solutions currently has a consensus target price of $32.00, suggesting a potential upside of 11.67%. CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 14.73%. Given CapsoVision's stronger consensus rating and higher probable upside, analysts clearly believe CapsoVision is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

BioLife Solutions beats CapsoVision on 9 of the 16 factors compared between the two stocks.

How does CapsoVision compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

In the previous week, Kestra Medical Technologies had 2 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for Kestra Medical Technologies and 2 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.93 beat Kestra Medical Technologies' score of 0.47 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kestra Medical Technologies has a net margin of -171.87% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-171.87%	-65.49%	-46.39%
CapsoVision	-198.87%	N/A	-136.03%

CapsoVision has lower revenue, but higher earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$59.81M	25.85	-$113.81M	-$3.96	N/A
CapsoVision	$13.56M	27.29	-$25.32M	-$2.34	N/A

Kestra Medical Technologies currently has a consensus target price of $27.40, indicating a potential upside of 3.46%. CapsoVision has a consensus target price of $8.50, indicating a potential upside of 14.73%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts plainly believe CapsoVision is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

CapsoVision beats Kestra Medical Technologies on 9 of the 14 factors compared between the two stocks.

How does CapsoVision compare to PROCEPT BioRobotics?

CapsoVision (NASDAQ:CV) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 2.3% of CapsoVision shares are held by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PROCEPT BioRobotics has a net margin of -31.82% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

CapsoVision currently has a consensus target price of $8.50, suggesting a potential upside of 14.73%. PROCEPT BioRobotics has a consensus target price of $40.42, suggesting a potential upside of 79.06%. Given PROCEPT BioRobotics' higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
PROCEPT BioRobotics	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

CapsoVision has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	27.29	-$25.32M	-$2.34	N/A
PROCEPT BioRobotics	$308.05M	4.17	-$95.57M	-$1.82	N/A

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 2 mentions for CapsoVision. PROCEPT BioRobotics' average media sentiment score of 1.70 beat CapsoVision's score of 0.93 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

PROCEPT BioRobotics beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does CapsoVision compare to Inspire Medical Systems?

CapsoVision (NASDAQ:CV) and Inspire Medical Systems (NYSE:INSP) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

CapsoVision currently has a consensus target price of $8.50, suggesting a potential upside of 14.73%. Inspire Medical Systems has a consensus target price of $81.05, suggesting a potential upside of 77.57%. Given Inspire Medical Systems' higher possible upside, analysts clearly believe Inspire Medical Systems is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Inspire Medical Systems	3 Sell rating(s)	13 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.05

94.9% of Inspire Medical Systems shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 2.2% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Inspire Medical Systems has a net margin of 14.33% compared to CapsoVision's net margin of -198.87%. Inspire Medical Systems' return on equity of 10.35% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Inspire Medical Systems	14.33%	10.35%	8.81%

In the previous week, Inspire Medical Systems had 1 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for Inspire Medical Systems and 2 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.93 beat Inspire Medical Systems' score of -0.67 indicating that CapsoVision is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inspire Medical Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Inspire Medical Systems has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	27.29	-$25.32M	-$2.34	N/A
Inspire Medical Systems	$915.25M	1.44	$145.42M	$4.49	10.17

Summary

Inspire Medical Systems beats CapsoVision on 11 of the 16 factors compared between the two stocks.

Get CapsoVision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CV vs. The Competition

Export

Metric	CapsoVision	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$370.18M	$2.94B	$4.35B	$12.20B
Dividend Yield	N/A	N/A	11.51%	5.90%
P/E Ratio	-3.17	14.60	22.03	24.19
Price / Sales	27.29	343.36	203.45	100.04
Price / Cash	N/A	8.09	38.01	53.91
Price / Book	26.46	5.97	13.53	6.36
Net Income	-$25.32M	$7.39M	$115.37M	$337.69M
7 Day Performance	12.09%	-3.51%	-1.17%	-0.32%
1 Month Performance	11.92%	-8.19%	-2.56%	0.33%
1 Year Performance	N/A	2.73%	10.85%	26.88%

CapsoVision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CV CapsoVision	1.1576 of 5 stars	$7.41 +6.0%	$8.50 +14.7%	N/A	$370.18M	$13.56M	N/A	90	News Coverage
ENOV Enovis	3.7566 of 5 stars	$21.34 -2.9%	$44.50 +108.5%	-31.9%	$1.23B	$2.25B	N/A	7,802	Positive News
BLFS BioLife Solutions	3.3106 of 5 stars	$24.90 -4.4%	$32.00 +28.5%	+28.7%	$1.22B	$96.21M	N/A	440	Positive News
KMTS Kestra Medical Technologies	1.6545 of 5 stars	$20.73 +4.0%	$27.40 +32.2%	+27.7%	$1.21B	$59.81M	N/A	300	News Coverage
PRCT PROCEPT BioRobotics	3.2179 of 5 stars	$21.06 -3.0%	$41.36 +96.4%	-63.1%	$1.20B	$308.05M	N/A	430	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CV) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CapsoVision (CV) Competitors

CV vs. ENOV, BLFS, KMTS, PRCT, and INSP

How does CapsoVision compare to Enovis?

Summary

How does CapsoVision compare to BioLife Solutions?

Summary

How does CapsoVision compare to Kestra Medical Technologies?

Summary

How does CapsoVision compare to PROCEPT BioRobotics?

Summary

How does CapsoVision compare to Inspire Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CapsoVision (CV) Competitors

CV vs. ENOV, BLFS, KMTS, PRCT, and INSP

How does CapsoVision compare to Enovis?

Do analysts rate CV or ENOV?

Which has higher earnings & valuation, CV or ENOV?

Does the media refer more to CV or ENOV?

Do insiders and institutionals have more ownership in CV or ENOV?

Is CV or ENOV more profitable?

Summary

How does CapsoVision compare to BioLife Solutions?

Do institutionals & insiders hold more shares of BLFS or CV?

Is BLFS or CV more profitable?

Does the media prefer BLFS or CV?

Which has higher earnings and valuation, BLFS or CV?

Do analysts prefer BLFS or CV?

Summary

How does CapsoVision compare to Kestra Medical Technologies?

Does the media favor KMTS or CV?

Is KMTS or CV more profitable?

Which has higher earnings & valuation, KMTS or CV?

Do analysts prefer KMTS or CV?

Summary

How does CapsoVision compare to PROCEPT BioRobotics?

Do institutionals and insiders have more ownership in CV or PRCT?

Is CV or PRCT more profitable?

Do analysts rate CV or PRCT?

Which has better valuation and earnings, CV or PRCT?

Does the media favor CV or PRCT?

Summary

How does CapsoVision compare to Inspire Medical Systems?

Do analysts rate CV or INSP?

Do insiders and institutionals have more ownership in CV or INSP?

Is CV or INSP more profitable?

Does the media prefer CV or INSP?

Which has higher earnings and valuation, CV or INSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools